Kiran Mazumdar Shaw- Biocon
Women entrepreneurs in India are expected to increase by up to 90% in the next five years, as women benefit from significant improvements in a variety of sectors. These shifting patterns may be seen in the growing majority of women entrepreneurs in Bangalore. Let us know more about Kiran Mazumdar Shaw, Biocon Co-Founder, and a Billionaire.
Local BangaloreTeam 
The nationwide research focuses on the problems faced by women entrepreneurs, as well as their influence on their health, socioeconomic security, and family well-being. It provides a comprehensive picture of women entrepreneurs and the environment in which they thrive. After launching a business, about 80% of women from semi-urban and rural India sense a major change in their socio-economic and cultural standing, according to research done across 13 states. The women polled also expressed a higher sense of independence and self-assurance.
Kiran Mazumdar Shaw- Biocon
Kiran is a highly renowned business executive who has been ranked among Time magazine's 100 most important people in the world. She is a pioneer of the biotech sector in India and the head of the country's top biotechnology organisation. She has been honoured with the Padma Shri and Padma Bhushan, two of India's highest civilian honours, for her contributions to biotechnology.
Kiran Mazumdar Shah, the Chairman and Managing Director of Biocon Limited, India's largest biotechnology business, earned her bachelor's degree in zoology and biology from Bangalore University with the intention of enrolling in a medical school. She was, however, unable to obtain a scholarship. With few choices, she chose to study fermentation science and train to be a brewmaster, as suggested by her father. She was the sole woman in her class at Ballarat College of Advanced Education in Australia, where she studied Malting and Brewing. She worked as a trainee Maltster and brewer at a few Australian companies after getting her Master Brewer's degree. Because a woman could not become a Master Brewer in India, she began looking for work overseas and was given a post in Scotland.
She met Leslie Auchincloss, the founder of Biocon Biochemicals Limited, just before travelling to Scotland, who was searching for an Indian entrepreneur to start a subsidiary in India. That was the start of Kiran's career as an entrepreneur. She worked as a Trainee Manager at Biocon Biochemicals Limited in Cork, Ireland, for a short time to learn the ropes. In 1978, she founded Biocon India with a capital of Rs 10,000, working out of the garage of her leased home. She encountered several hurdles in the beginning due to the unproven business strategy, her gender, and her lack of credibility. Her first employee, in fact, was a former garage mechanic. Her efforts were rewarded when Biocon became the first firm in India to manufacture enzymes and sell them to the United States and Europe within a year of its founding. Her firm has matured into a prominent player in biomedical research with a focus on diabetes and cancer, and she is now a billionaire.
Pandemic, Collab and Covid Survivor
Under the shadow of the COVID-19 epidemic, the last year has been eventful for Kiran on both a personal and professional level. She has such a strong regard for the scientific method as a result of her four-decade career as the CEO of a biopharmaceutical business. Her personal experience with COVID-19 confirmed the view that science would eventually lead everyone to a better knowledge of the world and teach how to live in it. She is also a Covid Survivor and shared her experience of tackling the coronavirus and wanting to educate the public about the way of diagnosing it at the right stage with the right medication under a physician's monitoring.
On a professional level, She enlisted the help of the scientific teams at Biocon Limited and Syngene to participate in the worldwide campaign to combat COVID-19 using cutting-edge research. Their psoriasis biologic medication ALZUMAb (Itolizumab) has been repurposed by Biocon's scientists to treat moderate to severe ARDS (acute respiratory distress syndrome) patients hospitalised with COVID-19. ALZUMAb was one of the COVID-19 medicines that they were able to promptly give to patients in India who were suffering from mild to moderate coronavirus infections. Syngene, one of its research services companies, significantly increased its efforts to combat COVID-19 by refocusing its scientific and technological resources in COVID-19-related areas. It established a COVID-19 testing facility utilising RT-PCR technology at its Bengaluru campus and began screening samples to assist local authorities. She believes that whether it is arts or sciences, we have much to be proud of in India," Mazumdar Shaw remarked.
Kiran Mazundar Shaw, CEO of Biocon, said India should be proud of its deeply ingrained talent in the arts and sciences.
